Cistron Biotechnology Inc Watch

from 10-K 1 page Non-Recourse Secured Promissory Note

from 10-K ~5 pages Waiver, Release and Termination Agreement

from 10-K ~10 pages Amendment to 1997 Stock Option Plan

from 8-K 1 page Letter Agreement

from 8-K ~10 pages Amendment to License Agreement

from 10-Q 1 page Non-Recourse Secured Promissory Note

from 10-Q ~20 pages License Agreement

from 10-Q 1 page Amendment #3 by This Amendment, Duke University ("Duke") and Cistron Biotechnology, Inc. ("Sponsor") Agree to Amend the Terms of the Clinical Study and Research Agreement Entered Into by the Parties Effective September 1, 1998 ("Agreement"), and Amended on December 18, 1999 and in March, 1999 as Follows: 1. the Parties Agree That Article 1, Statement of Work, Shall Be Further Expanded to Include the Research Described in an Additional Statement of Work, a Copy of Which Is Attached to This Agreement as Exhibit G. the Parties Also Agree That the Sponsor Shall Provide Additional Compensation to Duke for the Research Set Forth in Exhibit G in Accordance With the Terms Described in the Supplemental Budget Attached to This Agreement as Exhibit H. 2. the Parties Agree That Sponsor Shall Compensate Duke as Follows: $20,719.16 Shall Be Paid to Duke No Later That September 15, 1999. the Remaining Balance of $20,719.16 Shall Be Paid to Duke on Completion of the Research and Receipt by Cistron of a Final Report as Detailed in the Agreement. 3. the Parties Agree That the Terms of the Clinical Study and Research Agreement Shall Be Extended Through March 31, 2000 and May Be Extended Beyond That Date by Mutual Agreement of Both Parties. 4. All Other Terms of the Agreement Are Unchanged and Remain in Full Force and Effect. Agreed: Duke University Cistron Biotechnology, Inc. By: /S/Ralph Snyderman, M.D. By: /S/Richard S.DONDERO Ralph Snyderman, M.D. Name: Richard S. Dondero Chancellor for Health Affairs Title: Vice President - Operations and New Product Development Date: 9/8/99 Date: September 1, 1999 Acknowledged: By: /S/Herman F. Staats, PH.D. Herman Staats, PH.D. Principal Investigator

from 10-Q 1 page Amendment #2 by This Amendment, Duke University ("Duke") and Cistron Biotechnology, Inc. ("Sponsor") Agree to Amend the Terms of the Clinical Study and Research Agreement Entered Into by the Parties Effective September 1, 1998, ("Agreement") and First Amended on December 18, 1998 as Follows: 1. the Parties Agree That Article 1, Statement of Work, Shall Be Expanded to Include the Research Described in an Additional Statement of Work, a Copy of Which Is Attached to the Agreement as Exhibit C. the Parties Also Agree That the Sponsor Shall Provide Additional Compensation to Duke for the Research Set Forth in Exhibit C in Accordance With the Terms Described in the Supplemental Budget Attached to This Agreement as Exhibit D. 2. the Parties Agree That Article 1 Will Be Further Expanded to Include the Research Described in the Statement of Work Attached to This Agreement as Exhibit E. Likewise, the Parties Agree That Sponsor Shall Provide Additional Compensation to Duke for the Research Set Forth in Exhibit E in Accordance With the Terms Described in the Supplemental Budget Attached to This Agreement as Exhibit F. 3. the Parties Agree That the Term of the Clinical Study and Research Agreement Shall Be Extended Through December 31, 9999 and May Be Extended Beyond That Date by Mutual Agreement of Both Parties. 4. All Other Terms of the Agreement Are Unchanged and Remain in Full Force and Effect. Agreed: Duke University Sponsor By: /S/Ralph Snyderman, M.D. By: /S/Bruce C. Galton Ralph Snyderman, M.D. Bruce C. Galton Chancellor for Heath Affairs Chairman and CEO Date Executed: 3/17/99 Date Executed: 3-22-99 Acknowledged: By: /S/Herman F. Staats 3/19/99 Herman Staats, PH.D. Principal Investigator

from 10-Q 1 page Amendment #1 by This Amendment, Duke University ("Duke"), and Cistron Biotechnology, Inc. ("Sponsor") Agree to Amend the Terms of the Clinical Study and Research Agreement Entered Into by the Parties Effective September 1, 1998, ("Agreement") as Follows: 1. the Parties Agree That Article 5, Period of Performance, Is Revised So That the Research Will Be Conducted in an Ten-Month Period Commencing on September 1, 1998, and Concluding on or Before June 30, 1999. 2. All Other Terms of the Agreement Are Unchanged and Remain in Full Force and Effect. Agreed: Duke University Sponsor: By: /S/Ralph Snyderman, M.D. By: /S/Bruce C. Glaton Ralph Snyderman, MD Printed Name: Bruce C. Galton Chancellor for Health Affairs Title: Chairman & CEO Date Executed: 12/18/98 Date Executed: 12-16-98 Acknowledged: /S/Herman F. Staats Herman F. Staats Principal Investigator

from 10-Q ~5 pages Sponsored Research Agreement

from 10-K 1 page Amendment to Employment Agreement

from 8-K ~10 pages Purchase Agreement

from 8-K ~10 pages Purchase Agreement

from 10-Q ~10 pages Separation From Employment Agreement

from 10-Q ~5 pages License Areement

from 10-Q ~10 pages Engagement Letter

from 10-Q ~50 pages Collaboration and Option Agreement

from 10-Q ~10 pages Material contract

from 10-Q 1 page Material contract